Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Breast Cancer: Medication Use to Reduce Risk

About this resource:

Systematic Review

Source: U.S. Preventive Services Task Force

Last Reviewed: September 2019

Workgroups: Cancer Workgroup, Access to Health Services Workgroup

The U.S. Preventive Services Task Force (USPSTF) recommends that health care providers offer to prescribe risk-lowering medicines — like tamoxifen, raloxifene, or aromatase inhibitors — to women age 35 years and older who are at increased risk of breast cancer and low risk of side effects from the medicine. USPSTF recommends against use of these medicines in women age 35 years and older who aren't at increased risk for breast cancer.

Read more about this resource

Objectives related to this resource (2)

Increase the proportion of adults who get recommended evidence-based preventive health care — AHS‑08
Getting worse
Reduce the female breast cancer death rate — C‑04
Improving

Suggested Citation

1.

U.S. Preventive Services Task Force. (2019). Breast Cancer: Medication Use to Reduce Risk. Retrieved from https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction